Open AccessClinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation
Author(s) -
Xueyang Hu,
Wenjun Chen,
Xiaoqiu Li,
Chenchen Zhao,
Congjun Zhang,
Fenfen Xiong,
Hongyang Wang
Publication year - 2019
Publication title -
annals of palliative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.546
H-Index - 19
eISSN - 2224-5839
pISSN - 2224-5820
DOI - 10.21037/apm.2019.10.13
Subject(s) - medicine , osimertinib , adenocarcinoma , t790m , lung cancer , brain metastasis , oncology , chemotherapy , epidermal growth factor receptor , metastasis , radiation therapy , temozolomide , cancer , pathology , ros1
To find the method of therapy of leptomeningeal metastasis (LM) to non-small cell lung cancer (NSCLC) patient with EGFR mutation (EGFR+) but without T790M mutation.